We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+18.68%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.69B
AUM Growth
+$682M
Cap. Flow
-$395M
Cap. Flow %
-5.9%
Top 10 Hldgs %
54.02%
Holding
678
New
246
Increased
85
Reduced
72
Closed
235

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$85.8M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$59.6M
3
BCAX
Bicara Therapeutics
BCAX
+$45.8M
4
MRUS
Merus
MRUS
+$34.4M
5
VTRS icon
Viatris
VTRS
+$30M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$102M
2
SGRY icon
Surgery Partners
SGRY
+$86.4M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$53.7M
4
IART icon
Integra LifeSciences
IART
+$42.8M
5
BNTX icon
BioNTech
BNTX
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.45%
2 Industrials 0.73%
3 Technology 0.55%
4 Financials 0.45%
5 Consumer Discretionary 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RKT icon
401
Rocket Companies
RKT
$38.8B
$237K ﹤0.01%
+12,347
New +$217K
CMS icon
402
CMS Energy
CMS
$23B
$233K ﹤0.01%
3,297
-11,057
-77% -$726K
FOLD
403
DELISTED
Amicus Therapeutics
FOLD
$232K ﹤0.01%
21,723
-8,029
-27% -$87.4K
KLAC icon
404
KLA
KLAC
$222B
$232K ﹤0.01%
+2,990
New +$235K
J icon
405
Jacobs Solutions
J
$16B
$230K ﹤0.01%
+1,778
New +$214K
CCRN
406
DELISTED
Cross Country Healthcare
CCRN
$230K ﹤0.01%
+17,125
New +$252K
DOW icon
407
Dow Inc
DOW
$22B
$226K ﹤0.01%
+4,140
New +$219K
UTL icon
408
Unitil
UTL
$989M
$225K ﹤0.01%
+3,712
New +$217K
SWKS icon
409
Skyworks Solutions
SWKS
$9.2B
$224K ﹤0.01%
+2,268
New +$241K
ONTO icon
410
Onto Innovation
ONTO
$10.9B
$223K ﹤0.01%
1,073
-1,362
-56% -$275K
GL icon
411
Globe Life
GL
$14B
$218K ﹤0.01%
2,057
-3,013
-59% -$289K
ADEA icon
412
Adeia
ADEA
$2.55B
$217K ﹤0.01%
+18,254
New +$212K
ACLS icon
413
Axcelis
ACLS
$3.44B
$217K ﹤0.01%
2,067
-2,154
-51% -$252K
RGEN icon
414
Repligen
RGEN
$6.91B
$211K ﹤0.01%
1,418
-1,944
-58% -$279K
STR
415
DELISTED
Sitio Royalties
STR
$210K ﹤0.01%
+10,072
New +$228K
ARDX icon
416
Ardelyx
ARDX
$1.24B
$209K ﹤0.01%
+30,354
New +$179K
FLYW icon
417
Flywire
FLYW
$2.04B
$197K ﹤0.01%
+12,001
New +$210K
WT icon
418
WisdomTree
WT
$2.79B
$194K ﹤0.01%
+19,462
New +$198K
KEY icon
419
KeyCorp
KEY
$23.8B
$172K ﹤0.01%
+10,252
New +$163K
AAOI icon
420
Applied Optoelectronics
AAOI
$6.14B
$171K ﹤0.01%
+11,981
New +$124K
PATH icon
421
UiPath
PATH
$6.52B
$171K ﹤0.01%
+13,391
New +$164K
DDD icon
422
3D Systems Corp
DDD
$405M
$160K ﹤0.01%
56,349
+31,222
+124% +$89.8K
TDAY
423
USA Today Co
TDAY
$1.29B
$154K ﹤0.01%
+27,331
New +$133K
KALV
424
DELISTED
KalVista Pharmaceuticals
KALV
$153K ﹤0.01%
13,255
+2,414
+22% +$30.4K
CHGG icon
425
Chegg
CHGG
$116M
$151K ﹤0.01%
+85,244
New +$209K
15 16
17
18 19

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2024 Portfolio in Review

As of Q3 2024, Deerfield Management held 678 positions worth $6.69B, up 11% from $6.01B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $395M in Q3 2024, closing 235 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Industrials and Technology.

Against the trend, Deerfield Management opened a new position in Indivior Pharmaceuticals worth $49.7M.

  • Deerfield Management's largest Q3 2024 buy was Indivior Pharmaceuticals: 5,092,642 shares worth $49.7M.
  • Deerfield Management added most to Neurocrine Biosciences in Q3 2024, an estimated $85.8M increase.
  • Deerfield Management's biggest Q3 2024 reduction was Surgery Partners, cutting an estimated $86.4M.
  • Deerfield Management fully exited Gilead Sciences in Q3 2024, selling an estimated $102M.
  • Deerfield Management's ten largest holdings make up 54% of its $6.69B portfolio in Q3 2024.
  • Deerfield Management opened 246 new positions and closed 235 in Q3 2024.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $6.69B.

Based on Deerfield Management's 13F filing for Q3 2024, filed 14 Nov 2024.